The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
Open accessAbstract
Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H). Our aim was to investigate the incidence of ARIA during treatment with bapineuzumab, and evaluate associated risk factors.Methods Two neuroradiologists independently reviewed 2572 fluid-attenuated inversion recovery (FLAIR) MRI scans from 262 participants in two phase 2 studies of bapineuzumab and an open-label extension study. Readers were masked to the patient's treatment, APOE ɛ4 genotype, medical history, and demographics. Patients were included in risk analyses if they had no evidence of ARIA-E in their pre-treatment MRI, had received bapineuzumab, and had at least one MRI scan after treatment. We used Kaplan-Meier survival analysis to examine the distribution of incident ARIA-E from the start of bapineuzumab treatment and proportional hazards regression models to assess risk factors associated with ARIA.Findings 210 patients were included in the risk analyses. 36 patients (17%) developed ARIA-E during treatment with bapineuzumab; 15 of these ARIA-E cases (42%) had not been detected previously. 28 of these patients (78%) did not report associated symptoms. Adverse events, reported in eight symptomatic patients, included headache, confusion, and neuropsychiatric and gastrointestinal symptoms. Incident ARIA-H occurred in 17 of the patients with ARIA-E (47%), compared with seven of 177 (4%) patients without ARIA-E. 13 of the 15 patients in whom ARIA were detected in our study received additional treatment infusions while ARIA-E were present, without any associated symptoms. Occurrence of ARIA-E increased with bapineuzumab dose (hazard ratio [HR] 2·24 per 1 mg/kg increase in dose, 95% CI 1·40-3·62; p=0·0008) and presence of APOE ɛ4 alleles (HR 2·55 per allele, 95% CI 1·57-4·12; p=0·0001).Interpretation ARIA consist of a spectrum of imaging findings with variable clinical correlates, and some patients with ARIA-E remain asymptomatic even if treatment is continued. The increased risk of ARIA among APOE ɛ4 carriers, its association with high bapineuzumab dose, and its timecourse in relation to dosing suggest an association between ARIA and alterations in vascular amyloid burden.Funding Elan Corporation, Janssen Alzheimer Immunotherapy, Wyeth Pharmaceuticals, and Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The main adverse effects associated with administration of certain anti-Aβ mAbs during clinical trials were amyloid related imaging abnormalities (ARIA) identified on magnetic resonance imaging (MRI) scans.”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However one needs to be mindful that escalation of anti-Aβ mAbs dose in APOE ε4 allele carriers may trigger increased rate of vasculotropic adverse events associated with immunization [5, 8, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Some amyloid β antibodies triggered amyloid-related imaging abnormalities (ARIAs) in clinical trials and ARIAs tend to be more frequent in APOE4 carriers [28].”
From Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease (2017) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, ApoE ε4 status has gained direct clinical relevance in the anti-amyloid era”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“ε4 carriers, particularly ε4 homozygotes, exhibit a substantially increased risk of amyloid-related imaging abnormalities (ARIA) during treatment with anti-amyloid monoclonal antibodies [2, 5, 8].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Pathologic correlates of incidental MRI white matter signal hyperintensities
Fazekas, F., Kleinert, R., Offenbacher, H., Schmidt, R., Kleinert, G., Payer, F., Radner, H., & Lechner, H. (1993) · Neurology · doi:10.1212/wnl.43.9.1683 · Cited by 1,619
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Self-citationPrevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study
Vernooij, M. W., van der Lugt, A., Ikram, M. A., Wielopolski, P. A., Niessen, W. J., Hofman, A., Krestin, G. P., & Breteler, M. M. B. (2008) · Neurology · doi:10.1212/01.wnl.0000307750.41970.d9 · Cited by 793
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Self-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citationWeller, R. O., Subash, M., Preston, S., Mazanti, I., & Carare, R. O. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00133.x · Cited by 697
Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy
Greenberg, S. M., Rebeck, G. W., Vonsattel, J. P., Gómez‐Isla, T., & Hyman, B. T. (1995) · Annals of Neurology · doi:10.1002/ana.410380219 · Cited by 547
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Clinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
Cited by
Sorted by citations
Items 401–500 of 506
Mondal, A. C., & Sushma (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666211228100955 · Cited by 4
Passive Immunotherapy in Alzheimer’s Disease
Dolan, P. J., & Zago, W. M. (2018) · InTech eBooks · doi:10.5772/intechopen.76299 · Cited by 4
Muralidharan, K. K., Karumanchi, S., Kowalski, K. G., Burkett, P., Chapel, S. H., Rajagovindan, R., & Nestorov, I. A. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2047 · Cited by 4
Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy
Sotoudeh, H., Alizadeh, M., Shahidi, R., Shobeiri, P., Saadatpour, Z., Wheeler, C. A., Love, M. N., & Tanwar, M. (2024) · Frontiers in Radiology · doi:10.3389/fradi.2023.1305390 · Cited by 4
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 3
Hu, N., Yang, X., Feng, F., Zhang, B., Liu, Y., Gao, H., Chen, Q., Zhang, C.-J., Chen, X., Yan, F., et al. (2026) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-337198 · Cited by 3
Bigjahan, B., Cavallari, M., & Barisano, G. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1719740 · Cited by 3
Personalized medicine in old age psychiatry and Alzheimer’s disease
Siafarikas, N. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1297798 · Cited by 3
Amyloid related imaging abnormalities in the emergency setting
Czerminski, J. T., Khatri, S., & Rao, B. (2024) · Emergency Radiology · doi:10.1007/s10140-024-02286-2 · Cited by 3
Seifert, R. M., Rauch, M., Klingebiel, R., Boese, L.-M., Greeve, I., Rudwaleit, M., & Schäbitz, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1277843 · Cited by 3
Exploring AI’s Role in Managing Neurodegenerative Disorders: Possibilities and Hurdles
Mangalampalli, S., Karri, G. R., & Shaw, A. (2024) · Studies in computational intelligence · doi:10.1007/978-3-031-53148-4_7 · Cited by 3
Zuo, C., Hu, Z., Fan, Y., Hao, X., Li, M.-J., Shi, J.-J., Guo, M.-N., Ma, D., Liang, Y., Liang, Y.-Y., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1403077 · Cited by 4
Familial cerebral amyloid disorders with prominent white matter involvement
Banerjee, G., Schott, J. M., & Ryan, N. S. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-99209-1.00010-7 · Cited by 3
Kakeda, S., Miki, Y., Kudo, K., Mori, H., Tokumaru, A. M., Abe, O., Aoki, S., & Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, T. J. S. F. N. (2025) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.gl.2025-1000 · Cited by 3
Continuous event monitoring via a Bayesian predictive approach
Di, J., Wang, D., Brashear, H. R., Dragalin, V., & Krams, M. (2015) · Pharmaceutical Statistics · doi:10.1002/pst.1727 · Cited by 3
Self-citationStructural MRI in Alzheimer’s Disease
Last, B. S., Rizvi, B. M., & Brickman, A. M. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780190634230.003.0010 · Cited by 3
Kausale Therapie der Alzheimer-Krankheit: Amyloidantikörper
Pawlowski, M., & Warnecke, T. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01291-2 · Cited by 3
Ritchie, M., Witbracht, M. G., Nuño, M. M., Hoang, D. K., Gillen, D. L., & Grill, J. D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220801 · Cited by 3
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 3
Therapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
Stealth Attack: Plaque-Specific Antibody Allows for Efficient Aβ Removal without Side Effects
Roh, J. H., & Holtzman, D. M. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.018 · Cited by 3
Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now?
Charidimou, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151042 · Cited by 3
Immunotherapy: An Approach to Treat Alzheimer’s Disease and Autism Spectrum Disorder
Maarfi, F., Hasan, Z., Khanam, A., Husain, A., Khan, M. H., & Khan, M. Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-4558-7_11 · Cited by 3
Sowanou, A., Ungureanu, A., & Paulin, M. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01971-8 · Cited by 3
Reply to: Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease
McDade, E. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15826 · Cited by 3
Naeshiro, Y., Kitani‐Morii, F., Kasai, T., Tanaka, E., Kobayashi, F., & Ohara, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6070-25 · Cited by 2
Cai, M., Lei, H., Zhang, Y., Zou, J., Cao, W., Wang, Y., Wei, K., & Initiative, T. A. D. N. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1847611 · Cited by 2
Wu, S., Qi, Y., Jiang, C., & Zheng, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2448205 · Cited by 2
Radiological Findings of Drug-Induced Neurotoxic Disorders
Godi, C., & Falini, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-61423-6_67-1 · Cited by 2
Immunotherapy in Alzheimer’s Disease
Gupta, J., & Hoque, M. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_14 · Cited by 2
Neuroinflammation in Alzheimer's Disease
(2020) · Case Medical Research · doi:10.31525/ct1-nct04274998 · Cited by 2
Transport of Protein and Antibody Therapeutics Across the Blood–Brain Barrier
Pardridge, W. M. (2015) · Wiley eBooks · doi:10.1002/9781118788523.ch8 · Cited by 2
Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era
Coraglia, F., Cecchetti, G., Rugarli, G., Spinelli, E. G., Ghirelli, A., Pisano, S., Canu, E., Filippi, M., & Agosta, F. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02089-2 · Cited by 1
Strope, T. A., Troutwine, B., Hauger, B. M., Smith, K. P., Swerdlow, R. H., & Wilkins, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251360243 · Cited by 2
Kang, S., Kafetsouli, D., Ford, J., Wong, J., Bracoud, L., Suhy, J., Giannakopoulou, P., Udeh‐Momoh, C. T., Russ, T. C., Ritchie, C. W., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70594 · Cited by 1
Wiest, R., Radojewski, P., Lieb, J., Psychogios, M., Benzinger, T. L. S., Franceschi, A. M., Wanke, I., Draganski, B., Kurz, F. T., & Lövblad, K. (2025) · Neurodegenerative Diseases · doi:10.1159/000549521 · Cited by 1
Chimal‐Juárez, E., Jury, N., Gómez-Isaza, L., Troncoso, J. C., & Lasagna‐Reeves, C. A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71208 · Cited by 3
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
Takahashi, R., Kashibayashi, T., Fujita, J., Yoshida, K., Hashiramoto, A., Kowa, H., & Mizuta, E. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261488874 · Cited by 1
Amyloid-Related Imaging Abnormalities Associated With Immunotherapy In Alzheimer‘s Disease Patients
Panza, F., Frisardi, V., Imbimbo, B. P., Logroscino, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2012) · Future Neurology · doi:10.2217/fnl.12.42 · Cited by 1
Pathophysiology of Lymphatic Drainage of the Central Nervous System
Weller, R. O., Carare, R. O., Hawkes, C. A., & Galea, I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800763-1.00019-1 · Cited by 1
Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know
Alsufayan, R., Hess, C. P., & Krings, T. (2023) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7974 · Cited by 1
Clinicoradiological features of cerebral microbleeds diagnosed on magnetic resonance neuroimaging
Bharath, J., Amuthabharathi, M., Sivasubramaniyan, K. M., Adithan, S., Narayan, S. K., Sunitha, V. C., & Nagarajan, K. (2024) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_331_2023 · Cited by 1
Challenges and proposed solutions to conducting Alzheimer’s disease psychosis trials
Ballard, C. G., Tariot, P. N., Soto‐Martin, M., Pathak, S. S., & Liu, I.-Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1384176 · Cited by 1
Literature review of Alzheimer’s disease aetiology
Al-Momani, H. (2024) · Medicus · doi:10.58944/jsur6977 · Cited by 1
Management of Alzheimer’s Disease Using disease-modifying Drugs
Gauthier, S. G. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.37 · Cited by 1
Lin, C., Fann, J. C., Chen, S. L., Chen, H.-H., & Yang, K. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190612162121 · Cited by 1
The future of dementia prevention and treatment strategies
直行, 里. (2020) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.57.374 · Cited by 1
Therapieentwicklungen bei der Alzheimer-Krankheit
Grimmer, T. (2022) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1802-4837 · Cited by 1
Magnetic Resonance Imaging in Pharmaceutical Safety Assessment
Hockings, P. D., & Beckmann, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-73317-9_19-1 · Cited by 1
Amyloid related imaging abnormalities (ARIA)
Gaillard, F., Sharma, R. S., & Froemmel, N. (2021) · Radiopaedia.org · doi:10.53347/rid-92312 · Cited by 1
Gregoire, S. M. (2014) · UCL Discovery (University College London) · Cited by 1
Rezaii, N., Dickson, J., Ford, J. N., He, Y., Katsumi, Y., Ramirez-Gomez, L. A., Lam, A. D., Shah, H., Arnold, S. E., Avetisyan, M., et al. (2026) · medRxiv · doi:10.64898/2026.01.23.26344739 · Cited by 1
Plowey, E. D., Abettan, J., Chou, P. C., Lye‐Barthel, M., Amaral, A. C. S., Sebalusky, J., Hamann, S., Srinivasan, J., Brown, R. Z., Fang, Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702402 · Cited by 1
Synapses, spines, zinc and pathology of Alzheimer's disease.
Familtsev, D. (2013) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/420 · Cited by 1
Charidimou, A. (2015) · UCL Discovery (University College London) · Cited by 1
Cognitive Enhancers and Treatments for Alzheimer's Disease
Devanand, D. P. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch109
Un traitement de la maladie d’Alzheimer ?
Sellal, F. (2012) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2012.07.013
Targeting cytotoxic species in amyloid diseases
Persson, M. (2012)
Beta-Amyloid-orientierte Therapien der Alzheimer-Krankheit
Grimmer, T. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0840-3
Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease
Yang, S., Kim, J., & Kim, Y. S. (2015) · Springer eBooks · doi:10.1007/978-4-431-55763-0_22
Open questions for Alzheimer's disease
Golde, T. E. (2014)
Une démence rapidement progressive : l’angiopathie amyloïde cérébrale subaiguë inflammatoire
Charef, S., Leblanc, A., Guibourg, B., Quintin‐Roué, I., Salem, D. B., & Zagnoli, F. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.003
3D printing of beta-amyloid protein deposits along capillary walls
Blue, C., Horowitz, S. S., & Snyder, P. J. (2017) · Journal of Biomedical Graphics and Computing · doi:10.5430/jbgc.v7n1p8
Tau-Directed Immunotherapy for Alzheimer's Disease
Schroeder, S. K. (2017) · Digital Commons - University of South Florida (University of South Florida)
Borgers, H. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6363
Atypical Alzheimer’s Disease, Mixed Dementia, and Amyloid Angiopathy
Cummings, J. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-56484-5_5
"Commentary: The ageing as a therapeutic target for Alzheimer's disease"
Castro-Fuentes, R. (2017) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2017/8.1144
Alzheimer’s disease syndrome – Recognizing the complexity of dementia
Kokjohn, T. A., Serrano, G. E., & Roher, A. E. (2017) · Neurological Disorders and Therapeutics · doi:10.15761/ndt.1000116
Traitement de la maladie d’Alzheimer : une lueur au bout du tunnel ?
Pariente, J., Rafiq, M., Bénaiteau, M., Gouilly, D., Pomies, E., Jasse, L., Drif, A., Calvas, F., Payoux, P., Rascol, O., et al. (2019) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2019.12.003
Investigating the role of normal and abnormal beta-amyloid processing in cognition
Freeman, T. J. (2019) · ORCA Online Research @Cardiff (Cardiff University)
Cerebral Amyloid Angiopathy: Emerging Evidence for Novel Pathophysiology and Pathogenesis
Yamada, M., Sakai, K., Hamaguchi, T., & Noguchi‐Shinohara, M. (2020) · Stroke revisited · doi:10.1007/978-981-10-1430-7_7
Parsons, M., Shin, M., Pascoal, T. A., Chamoun, M., Therriault, J., Soucy, J., Gauthier, S. G., & Rosa‐Neto, P. (2021) · Cambridge University Press eBooks · doi:10.1017/9781316941294.008
Watt, J. A., Marple, R., Hemmelgarn, B. R., & Straus, S. E. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.211134-f
Four cases of suspected cerebral amyloid angiopathy-related inflammation
Tsunoda, K., Wakutani, Y., Shibazaki, K., Ogawa, T., & Takao, Y. (2021) · Nosotchu · doi:10.3995/jstroke.10959
ALZHEIMER’S COGNITIVE IMPAIRMENT CAN BE CURED BY DECREASING BLOOD HOMOCYSTEIC ACID
Hasegawa, T., Uchida, T., & Chanoki, A. (2015) · Journal of Aging Research and Lifestyle · doi:10.14283/jarcp.2015.59
Reply to A Letter Concerning “Aducanumab: What About the Patient?”
Petersen, R. C. (2022) · Annals of Neurology · doi:10.1002/ana.26344
Faculty Opinions recommendation of Neuroinflammation in Alzheimer's disease.
Perani, D. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725413893.793537457
Effects of Aducanumab on treating Alzheimer’s disease: targets and clinical trials
Huang, B. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v6i.973
Harrison, C. H., Sakai, K., Johnston, D. A., Holmes, C., Boche, D., & Nicoll, J. A. R. (2022) · medRxiv · doi:10.1101/2022.12.08.22283144
Immunotherapies for Alzheimer’s Disease
Guo, H. J. (2022) · Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research · doi:10.2991/978-2-494069-31-2_344
Adaniya, S., Matsuda, H., Tomori, M., Kaneko, C., & Tomura, N. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005173
Kelley, M. A., & Bertelson, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197690024.003.0006
Genomics of Alzheimer’s disease
Rosenberg, R. N., Lambracht‐Washington, D., Yu, G., & Xia, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00035-2
Magnetic Resonance Imaging in Pharmaceutical Safety Assessment
Hockings, P. D., & Beckmann, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_19
An, D., Li, X., & Xu, Y. Y. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111576
5. Advances in Alzheimer's Therapeutics
Iwatsubo, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.92a
5. Advances in Alzheimer's Therapeutics
Iwatsubo, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1544
Uekawa, K., Hattori, Y., Ahn, S. J., Seo, J., Casey, N., Anfray, A., Zhou, P., Luo, W., Anrather, J., Park, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24240134
Leroi, I., Dolphin, H., Dinh, R., Foley, T., Kennelly, S., Kinchin, I., Ó’Caoimh, R., O’Dowd, S., O’Philbin, L., O’Reilly, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25980512
Pikus, P., Healey, G. S., Xia, E., Shautidze, G., Siddapureddy, N., Lee, Y., Albanese, C., Rodriguez, O. C., Turner, R. S., & Rebeck, G. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.09.704876
Mueller, A., Jovalekic, A., Chapleau, M., Seidel, J., Ritter, M., Bickel, E., Kiessling, N., MacSweeney, E., Stephens, A. W., & Koglin, N. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02001-y
The spectrum of cerebral amyloid angiopathy-related inflammation
Norton, E. J. (2026) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2026.03.002
Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer
Epelbaum, S. (2015) · theses.fr (ABES) · doi:10.70675/ea81e5c2z5032z4474z9f96z59f62125a629
NEW DISEASE-MODIFYING THERAPIES IN ALZHEIMER’S DISEASE: A CLINICAL REVIEW OF LECANEMAB AND DONANEMAB
Ollik, K., Harenza, K., Taranowicz, M., Kowalczyk, O., Zdobylak, D., Kowalska, M., Zieba, A., Domin, M., Całka, J., & Ścibisz, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4885
MYRONETS, O. M., & Sholomon, S. M. (2026) · Ukrainian Neurological Journal · doi:10.30978/unj2026-1-11
Zedde, M., Basso, G., Piazza, F., & Pascarella, R. (2026) · Springer eBooks · doi:10.1007/978-3-032-23618-0_7
Iatrogenic Cerebral Amyloid Angiopathy
Zedde, M., Kaushik, K., Wermer, M. J. H., Piazza, F., & Pascarella, R. (2026) · Springer eBooks · doi:10.1007/978-3-032-23618-0_13
Metadata
- Authors
- Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Lieberburg, I., Arrighi, H. M., Morris, K. A., Lu, Y., Liu, E., Gregg, K. M., Brashear, H. R., Kinney, G. G., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- Butler Hospital (US)
- Imperial College London (GB)
- McGill University (CA)
- California Pacific Medical Center (US)
- UCL Queen Square Institute of Neurology (GB)
- Columbia University (US)
- University of Rochester Medicine (US)
- University of California, San Francisco (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- Corresponding author
- Sperling, Reisa
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 241-249
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC4063417
- OpenAlex
- W2122843800
- Cited by
- 512
- References
- 27
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 51 · 2023: 35 · 2022: 47 · 2021: 32 · 2020: 31 · 2019: 25 · 2018: 22 · 2017: 34 · 2016: 29 · 2015: 47 · 2014: 36 · 2013: 39 · 2012: 17
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10123)
- Elan
- National Institute on Aging (K24AG035007, P50AG005134, P30AG062421)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- amyloid-related imaging abnormalities, bapineuzumab, Alzheimer's disease, amyloid-beta, ARIA-E, ARIA-H, vasogenic edema, microhemorrhages, APOE ε4, dose-dependent risk, risk factors, FLAIR MRI, adverse events
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Retrospective Studies, Risk Factors, Amyloid beta-Peptides, Neuroimaging, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
